FREMONT, Calif. , Feb. 9, 2015 /PRNewswire/ --   Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab , President and Chief Executive Officer and David Rosenbaum Ph.D., Senior Vice

FREMONT, Calif. , Feb. 2, 2015 /PRNewswire/ --   Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that AstraZeneca's 161-patient Phase 2b clinical trial evaluating tenapanor in

FREMONT, Calif. , Dec. 1, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced the appointment of Jeremy S. Caldwell , Ph.D., as Executive Vice President and Chief Scientific

-- Data Published Online in the Journal of the American Society of Nephrology --

Phase 2 Programs for Lead Product Candidate Tenapanor Continue to Advance in Multiple IndicationsArdelyx Updates Projected Timing of Results from Phase 2b Study in ESRD patients with HyperphosphatemiaConference Call and Webcast Today at 4:30 p.m. ET

FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014 .

FREMONT, Calif. , Oct. 23, 2014 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Ardelyx , together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will

-- Primary endpoint was met for 50 mg twice daily dosing --

FREMONT, Calif. , Sept. 5, 2014 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Dominique Charmot , Ph.D., the Company's Chief Scientific Officer, has announced his

Successfully Completed Initial Public Offering; Raised Net Proceeds of $61.2 MillionCompany Progressing Clinical Development of Lead Candidate, Tenapanor, In Three Ongoing Phase 2 Programs